12:18 PM
 | 
Nov 10, 2017
 |  BioCentury  |  Emerging Company Profile

Computing care

How Tempus is using machine learning to help docs choose cancer treatments

Tempus Labs Inc. has created a machine learning tool that can help physicians make better treatment decisions by comparing a cancer patient’s genetic and clinical profile to those of thousands of other patients with known treatment outcomes.

The tool supplements molecular profiling conducted in the company’s CLIA lab by placing the results in the context of a vast set of data -- including genetic information, pathology reports, physician notes and treatment outcomes -- that are otherwise unavailable to treating oncologists.

“No other single company out there is bringing this all together to help physicians make data-driven treatment decisions,” President Kevin White told BioCentury.

CEO and co-founder Eric Lefkofsky told BioCentury Tempus was borne of frustration from navigating treatment options when his wife was diagnosed with breast cancer in 2014. “I was perplexed at how little data permeated care,” he said. “It became apparent that the only way to usher in precision medicine was to fix the underlying data...

Read the full 772 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >